BMS has reported topline outcomes from the ARISE trial of Cobenfy as an adjunctive treatment to atypical antipsychotics for ...

Gilead Sciences has reported positive topline data from the Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy and MSD’s ...

The impact of long-acting injectables (LAIs) for HIV was discussed at the 35th ESCMID Global conference in Vienna, Austria.

Daiichi and AstraZeneca's Enhertu with pertuzumab has shown PFS improvement in the Phase III DESTINY-Breast09 trial.

Enlivex has completed the enrollment of all subjects in the Phase II stage of the Phase I/II trial of Allocetra for severe ...

A Phase I/II trial by Japan’s Kyoto University Hospital and CiRA team has demonstrated outcomes with allogeneic iPS ...

Advarra has integrated its Center for IRB Intelligence (CIRBI) with the Study Collaboration for visibility into trial site ...

With trial costs rising over the past decade and concerns they’ll keep climbing, companies are seeking ways to manage ...

Alzheon's Alzheimer's drug showed nominal benefit in a subgroup of patients who suffer with mild cognitive impairment.

Genesis has gained US Food and Drug Administration (FDA) clearance on an Investigational New Drug (IND) application for a ...

Seismic Therapeutic has dosed the first healthy participant cohort in the randomised Phase I trial of bifunctional antibody S ...

Pheast Therapeutics has treated the first subject in a multi-centre Phase I trial for PHST001, aimed at treating advanced ...